Presentation is loading. Please wait.

Presentation is loading. Please wait.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Charles.

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Charles."— Presentation transcript:

1 Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Charles Leduc, MD, Derek Kohler, MD, Mauro A. Saieg, MD, PhD, Thomas John, MBBS, PhD, Jenna Sykes, MSc, MMath, Maisa Yoshimoto, MSc, PhD, Melania Pintilie, MSc, Jeremy Squire, PhD, Frances A. Shepherd, MD, FRCPC, Ming-Sound Tsao, MD, FRCPC  Journal of Thoracic Oncology  Volume 7, Issue 10, Pages (October 2012) DOI: /JTO.0b013e d4f Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Representative images of PTEN immunohistochemistry. A, Low magnification and (B) high magnification, tumor showing complete lack of staining for PTEN. C, Low magnification and (D) high magnification, tumor showing positive staining for PTEN. PTEN, phosphatase and tensin homolog. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Representative photographs (100× magnification) of dual-color fluorescent in situ hybridization of non–small-cell lung tumors using probes for PTEN (green/FITC) and the centromere of chromosome 10 centromeric probe (blue/aqua), with grayscale 6-diamidino-2-phenylindole nuclear stain: A, PTEN diploidy; (B), PTEN hemizygous loss as predominant pattern; (C), PTEN hemizygous loss with chromosome 10 monosomy as predominant pattern; (D), PTEN homozygous loss as predominant pattern. PTEN, phosphatase and tensin homolog. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan–Meier DFS curves based on PTEN immunohistochemistry status. A, All patients based on PTEN status showing PTEN negative tumors were associated with poorer DFS compared with PTEN positive tumors. Adenocarcinomas (B) and (C) squamous cell carcinoma, according to PTEN status demonstrating significant differences in DFS based on histology. PTEN, phosphatase and tensin homolog; DFS, disease-free survival; CI, confidence interval; HR, hazard ratio. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d4f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Charles."

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine  Stéphane Collaud, MD, MSc, Thomas K.

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine  Stéphane Collaud, MD, MSc, Thomas K.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,
Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization  Willam Sterlacci, MD, Spasenija Savic, MD, Michael Fiegl,

Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization  Willam Sterlacci, MD, Spasenija Savic, MD, Michael Fiegl,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Similar presentations

Ads by Google